HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Pignone, M. Search for Related Content PubMed Articles by Pignone, M. Social Bookmarking                What's this?

Rosiglitazone Reduced the Incidence of Diabetes in Patients With Impaired Glucose Tolerance

The first 20% of the full text of this article appears below.

	STUDY

 
DREAM (Diabetes REduction Assessment with ramipril and rosiglitizone Medication) Trial Investigators; Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman, B, Holman RR: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet368 : 1096-1105,2006[Medline]

	SUMMARY

 
Design. A randomized, placebo-controlled, double-blind trial.

Subjects. Adults > 30 years of age with impaired fasting glucose (IFG; fasting plasma glucose [FPG] > 110 mg/dl and < 126 mg/dl and 2-hour plasma glucose < 200 mg/dl during oral glucose tolerance test [OGTT]) or impaired glucose tolerance (IGT; FPG < 126 mg/dl and 2-hour plasma glucose 140-200 mg/dl and no previous history of diabetes or cardiovascular disease).

Methods. Potentially eligible patients entered a placebo run-in period; those who were successful in taking . . . [Full Text of this Article]

	COMMENTARY

 

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?